Zobrazeno 1 - 10
of 424
pro vyhledávání: '"Shiro NAKAMURA"'
Autor:
Masanori Dantsuji, Ayako Mochizuki, Kiyomi Nakayama, Mitsuko Kanamaru, Masahiko Izumizaki, Kenji F. Tanaka, Tomio Inoue, Shiro Nakamura
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract The serotonergic system modulates the neural circuits involved in jaw movement; however, the role of serotonin (5-HT) neurons in masticatory movement remains unclear. Here, we investigated the effect of selective activation of 5-HT neurons i
Externí odkaz:
https://doaj.org/article/80e1bd2e36e94e95a63fb8a8b7005d58
Autor:
Yuki Hirata, Yoshiki Tanaka, Haruka Yokota, Hiroshi Ohno, Koji Nishida, Hikaru Shimizu, Noboru Mizuta, Kei Nakazawa, Ryoji Koshiba, Kazuki Kakimoto, Takako Miyazaki, Shiro Nakamura, Hiroki Nishikawa
Publikováno v:
Gut Pathogens, Vol 16, Iss 1, Pp 1-5 (2024)
Abstract Background Immune checkpoint inhibitors (ICIs) are crucial in cancer treatment; however, they carry the risk of immune-related adverse events (irAEs), such as enteritis. Case presentation: This study investigated the role of the gut microbio
Externí odkaz:
https://doaj.org/article/2133d2f175724209a0931aea4e11aea9
Autor:
Naohito Ito, Mayumi Tsuji, Naoki Adachi, Shiro Nakamura, Avijite Kumer Sarkar, Kensuke Ikenaka, César Aguirre, Atsushi Michael Kimura, Yuji Kiuchi, Hideki Mochizuki, David B. Teplow, Kenjiro Ono
Publikováno v:
npj Parkinson's Disease, Vol 9, Iss 1, Pp 1-10 (2023)
Abstract α-Synuclein (αS), the causative protein of Parkinson’s disease and other α-synucleinopathies, aggregates from a low molecular weight form (LMW-αS) to a high molecular weight αS oligomer (HMW-αSo). Aggregated αS accumulates intracell
Externí odkaz:
https://doaj.org/article/228a52955c864033bfc56882d062d772
Autor:
Ryoji Koshiba, Kazuki Kakimoto, Noboru Mizuta, Keijiro Numa, Naohiko Kinoshita, Kei Nakazawa, Yuki Hirata, Takako Miyazaki, Kazuhide Higuchi, Shiro Nakamura, Hiroki Nishikawa
Publikováno v:
PLoS ONE, Vol 19, Iss 8, p e0305324 (2024)
Background and aimUstekinumab, a new anti-interleukin-12/23 antibody, is an effective treatment for ulcerative colitis; however, data regarding predictive factors of its efficacy are limited. Predicting treatment efficacy in advance would be useful f
Externí odkaz:
https://doaj.org/article/fbfd73a5980e490d804baca3ecb1501d
Autor:
Hiroshi Nakase, Yuki Hayashi, Yoshihiro Yokoyama, Takayuki Matsumoto, Minoru Matsuura, Hideki Iijima, Katsuyoshi Matsuoka, Naoki Ohmiya, Shunji Ishihara, Fumihito Hirai, Daiki Abukawa, Tadakazu Hisamatsu, Makoto Sasaki, Masahiro Iizuka, Mikihiro Fujiya, Fukunori Kinjo, Shiro Nakamura, Noriko Kamata, Yuri Etani, Fumiaki Ueno, Sakiko Hiraoka, Takeo Kondo, Takashi Kagaya, Makoto Naganuma, Kiyonori Kobayashi, Taku Kobayashi, Shuji Yamamoto, Yuji Naito, Yoki Furuta, Keichi Mitsuyama, Yu Hashimoto, Katsuhiro Arai, Shingo Kato, Itaru Iwama, Motohiro Esaki, Hiroki Tanaka, Satoshi Motoya, Atsuo Maemoto, Toshifumi Ashida, Nobuaki Nishimata, Shigeaki Aono, Akira Andoh, Hironori Yamamoto, Toshiaki Shimizu, Maeda Yasuharu, Kenji Kinoshita, Katuyuki Fukuda, Jun Kato, Ken Takeuchi, Masakazu Nagahori, Masakatsu Fukuzawa, Masayuki Saruta, Takayoshi Suzuki, Michio Itabashi, Masaru Shinozaki, Soichiro Ishihara, Naoki Yoshimura, Yoichi Kakuta, Kenichi Takahashi, Keiichi Tominaga, Ryosuke Sakemi, Sohachi Nanjo, Shusaku Yoshikawa, Keiji Ozeki, Ayako Fuchigami, Takehiko Katsurada, Kenji Watanabe, Hirotake Sakuraba, Takashi Hisabe, Shigeru Iwase, Ryota Hokari, Katsuhiko Nakai, Takeshi Ueda, Shojiro Yamamoto, Kazutaka Koganei, Reiko Kunisaki, Akira Hokama
Publikováno v:
Gastro Hep Advances, Vol 2, Iss 8, Pp 1056-1065 (2023)
Background and Aims: Japan has experienced 8 waves of the coronavirus disease 2019 (COVID-19) outbreak over the past 3 years, resulting in an increasing number of deaths and incidence of severe infections. This study aimed to analyze the data from th
Externí odkaz:
https://doaj.org/article/6dc0fa435835412099a962069329f0e1
Autor:
Shiro Nakamura, Teita Asano, Hiroaki Tsuchiya, Kanami Sugimoto, Yuya Imai, Seiji Yokoyama, Yasuo Suzuki
Publikováno v:
Intestinal Research, Vol 20, Iss 3, Pp 329-341 (2022)
Background/Aims Golimumab (GLM) is an anti-tumor necrosis factor-α drug approved for treating moderate-to-severe active ulcerative colitis (UC). A 52-week post-marketing surveillance (PMS) was initiated to evaluate its safety and effectiveness in pa
Externí odkaz:
https://doaj.org/article/71e114b21acf4f648efaa0b86a6ec480
Autor:
Shiro Nakamura, Teita Asano, Yoshihito Tanaka, Kanami Sugimoto, Shinichi Yoshigoe, Yasuo Suzuki
Publikováno v:
Inflammatory Intestinal Diseases (2022)
Introduction: Real-world evidence for the effectiveness and safety of golimumab (GLM) in patients with ulcerative colitis (UC) is limited. The aim of this study was to investigate the 52-week effectiveness and safety of GLM treatment for UC. Methods:
Externí odkaz:
https://doaj.org/article/41b73e39759c4bd9b4f987ad46c0f1e2
Autor:
Kento Nakai, Takahiro Shiga, Rika Yasuhara, Avijite Kumer Sarkar, Yuka Abe, Shiro Nakamura, Yurie Hoashi, Keisuke Kotani, Shoji Tatsumoto, Hiroe Ishikawa, Yasuhiro Go, Tomio Inoue, Kenji Mishima, Wado Akamatsu, Kazuyoshi Baba
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract The serotonin 5-HT2A receptor (5-HT2AR) has been receiving increasing attention because its genetic variants have been associated with a variety of neurological diseases. To elucidate the pathogenesis of the neurological diseases associated
Externí odkaz:
https://doaj.org/article/9ace7684b2994563aa3aab287a2d11fb
Autor:
Avijite Kumer Sarkar, Shiro Nakamura, Kento Nakai, Taro Sato, Takahiro Shiga, Yuka Abe, Yurie Hoashi, Tomio Inoue, Wado Akamatsu, Kazuyoshi Baba
Publikováno v:
Stem Cell Research, Vol 59, Iss , Pp 102658- (2022)
Sleep bruxism (SB) is a sleep-related movement disorder characterized by grinding and clenching of the teeth during sleep. We previously found a significant association between SB and a single nucleotide polymorphism (SNP), rs6313, in the neuronal se
Externí odkaz:
https://doaj.org/article/c229fdb852f24dda82cebbd84c52c720
Autor:
Toshifumi Hibi, Satoshi Motoya, Toshifumi Ashida, Souken Sai, Yukinori Sameshima, Shiro Nakamura, Atsuo Maemoto, Masahiro Nii, Barbara A Sullivan, Robert A. Gasser Jr, Yasuo Suzuki
Publikováno v:
Intestinal Research, Vol 17, Iss 3, Pp 375-386 (2019)
Background/Aims Inhibition of α4β7 integrin has been shown to be effective for induction and maintenance therapy in patients with ulcerative colitis (UC). We investigated the effects of varying doses of the α4β7 inhibitor abrilumab in Japanese pa
Externí odkaz:
https://doaj.org/article/d66650684ad94dc38e466d1c0c33002c